INTRODUCTION
Colorectal cancer (CRC) is the third most common type of cancers and over millions of patients has been diagnosed annually. Main curative treatment for CRC primarily depends on surgical resection followed by radiation and chemotherapy. This treatment, however, often results in unsatisfactory outcome especially for the patients undergoing metastasis and in advanced stages, which requires the development of new therapeutic approaches (Wolpian & Mayer, 2008) .
Mutations in CRC are frequently found in protooncogenes encoding RAS (approximately 40%), PI3K (15-30%) and BRAF (15%), which in normal cells stimulate the cellular growth and proliferation in response to growth factors (Laurent-Puig et al., 2009 ). The activating mutations of these oncogenes results in aberrant cell proliferation via a series of signaling casades, mainly the RAS/RAF/MEK/ ERK and PI3K/Akt/mTOR pathways, which thus play important roles in the regulation of malignant cell proliferation (Mendoza et al., 2011) . Therefore, development of inhibitors targeting these pathways has become an attractive therapeutic strategy and such molecular targeting drugs have been actively searched and tested clinically and preclinically. One of such agents is the imidazoquinoline derivative BEZ235, a novel and orally bioavailable dual inhibitor of PI3K and mTOR. This compound inhibits PI3K and mTOR kinase activities by binding to the ATP binding cleft of these enzymes (Maira et al., 2008) and is currently being evaluated in phase I/II clinical trials in patient with solid tumors including CRC (Roper et al., 2011; Blaser et al., 2012) .
Most cancer therapeutic approaches, either chemotherapy or targeted therapy, have focused on induction of cell death and inhibition of cell growth. Resistance to anticancer drugs, however, compromises treatment outcome and limits the effectiveness of cancer treatment (Szakacs et al., 2006) . Drug resistance can result from a variety of mechanisms such as tumor cell heterogeneity, drug efflux, metabolism, autophagy induction, and genetic and epigenetic alterations as a cellular response to drug exposure (Sui et al., 2013) .
Autophagy is a lysosomal catabolic process which is essential for regulation of cell survival and death to keep cellular homeostasis. Substantial evidence suggests that autophagy has dual roles in cancers, acting as either prosurvival or prodeath mechanism against chemotherapy treatment, which contributes to the anticancer efficay as well as drug resistance (Shigemitsu et al., 1999; Takeuchi et al., 2005; Sui et al., 2013) . Many anti-cancer drugs including targeted therapies induce autophagy as a protective and prosurvival mechanism and blockage of autophagy thus augments the cytotoxic effect of chemotherapeutic agents (Li et al., 2013b) . On the other hand, excessive and persistent autophagy may induce autophagic cell death following chemotherapeutic agents (Li et al., 2013a) . One of the main regulators of autophagy is mTOR, and inhibitors of mTOR such as rapamycin and BEZ235 are reported to induce autophagy in urothelial and renal cancer cell (Li et al., 2013a (Li et al., , 2013b . Although previous studies have showed that inhibition of autophagy potentiates the anticancer effect of targeted therapy in CRC (Yang et al., 2010) , there is no report to examine the effectiveness of a novel dual PI3K/mTOR inhibitor BEZ235 as an anticancer drug in relation to autophagy induction in CRC cell.
The present study, therefore, was designed to elucidate the effects of BEZ235 on cell viability, cell cycle distribution, apoptosis and autophagy induction using human CRC cell line HCT15. In addition, we examined whether inhibition of autophagy by autophagy inhibitor chloroquine (CQ) may potentiate or decrease the anticancer activity of BEZ235 in HCT15 CRC cells.
MATERIALS AND METHODS

Cell culture and reagents
The human colorectal cancer cell line HCT15 was obtained from the American Type Culture Collection (Manassas, VA). Cells were grown in a monolayer culture in DMEM (Sigma) supplemented with 10% fetal bovine serum (Sigma) and 1% streptomycin/penicillin, and were maintained at 37°C in a humidified atmosphere consisting of 5% CO 2 and 95% air. Cells were regularly tested for mycoplasma contamination by treating 5 μg/mL of Plasmocin (InvivoGen).
BEZ235 was purchased from LC laboratories (Woburn, MA).
CQ, acridine orange, 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) were all purchased from Sigma.
Cell viability assay
To determine the effects of BEZ235 on HCT15 cell viability, we used MTT assay as described previously 
Western blot
Western blot assays were performed as described previously (Song et al., 2011) Cells were analyzed using BD FACSCalibur Flow Cytometry System and data were analyzed using CellQuest software. (1 μg/mL) in HBSS containing 5% FBS for 15 minutes and then observed with a fluorescence microscope.
Statistical analysis
Data were expressed in the form of mean ± SEM. The statistical analysis was done using Student's t Test. Differences between means were considered as significant when yielding p<0.05.
RESULTS
BEZ235 inhibits the cell viability and affects ERK and Akt activity in HCT15 CRC cells
To delineate by flow cytometry using PI staining is shown in Fig. 2A . 
Inhibition of autophagy induced by BEZ235 treatment rescues the cell viability in HCT15 CRC cells
Next, we asked whether inhibition of autophagy affects the growth inhibition in response to BEZ235 treatment. To this end, we used a lysosomotropic agent chloroquine (CQ), which inhibits the fusion of autophagosomes with lysosome and thus commonly employed as an autophagy inhibitor (Mizushima et al., 2010) . Recently, however, several reports suggest that high doses of CQ can promote lysosomal membrane permeabilization, resulting in lysosome-mediated apoptosis (Seitz et al., 2013; . Therefore, we determined the dose of CQ which effectively inhibits autophagy without affecting the cell viability of HCT15 cells. As shown in Fig. 4A , CQ at 5 and 10 uM did not affect cell viability while CQ above 20 uM resulted in decreased cell survival compared with control. CQ has been known to induce the accumulation of AVOs since CQ inhibits the late step of autophagy blocking the fusion of autophagosome and lysosome (Sasaki et al., 2010) . In the present study, AO staining following CQ (5 and 10 μM) treatment showed the abundant red fluorescent AVOs, further confirming that CQ inhibits autophagy (Fig. 4B ). In the experiment to assess the effect of autophagy inhibition on cell viability in response to BEZ235 treatment, cells were co-treated with BEZ235 plus CQ. as demonstrated in other types of cancer cells (Maira et al., 2008; Xu et al., 2011) . On the contrary to reports using other tumor cells (Xu et al., 2011; Li et al., 2013b) (Schult et al., 2012; Kuger et al., 2015) . Several studies also suggested that mTORC2 promotes the phosphorylation of Akt at Ser 473 and this feedback loop serves as a rescue mechanism of cells in response to mTOR kinase inhibition (Sarbassov et al., 2005; Guertin et al., 2006) . The decrease of ERK phosphorylation following BEZ235 treatment in the present study can result from the negative regulation between two signaling pathways. Such cross-inhibition is often found when one pathway is chemically blocked, hence releasing cross-inhibition and efffectively activating the other pathway (Mendoza et al., 2011) .
Numerous studies demonstrated the association of cell cycle arrest with cancer therapeutic applications, and the inhibition of cell cycle has become a potential target for the treatment of cancer (Lee & Sicinski, 2006; Shapiro, 2006 arrest with the reduction of cyclin D expression Moon et al., 2014) , and cyclin A has been regarded as a S phase cyclin and its suppression induces S phase arrest in the cell cycle (Joe et al., 2002; Hung et al., 2013) .
The temporal relationship between cyclin A accumulation and DNA replication, however, showed that cyclin A accumulates precisely at the G 1 /S border and DNA replication does not take place before its accumulation in cancer cells (Erlandsson et al., 2000) . Therefore, considering that flow cytometry for the cell cycle analysis is based on DNA content within cell, the suppression of cyclin A seems to result in the increase of cell population in G 1 phase not in Recently, several groups already reported that BEZ235
induces autophagy in diverse cancer cell lines (Xu et al., 2011; Li et al., 2013a; Li et al., 2013b) . In the present study, we also found that BEZ235 causes significant autophagy in HCT15 CRC cells, evidenced by detection of increased levels of LC3B-II, a cleaved product of LC3B-1, and numerous AVO development by vital staining with AO. Considering that mTOR acts as a negative regulator of autophagy, it is not surprising to find induction of autophagy in cells treated with BEZ235, a dual PI3K/ mTOR inhibitor. Although it was suggested that many anticancer drugs used in chemotherapy and molecular targeted therapy stimulate autophagy, the role of autophagy on cell survival or cell death is controversial (Sui et al., 2013) . In our study, autophagy induced by BEZ235 appears to be cell destructive, since the combination treatment of BEZ235
with the autophagy inhibitor CQ counteracts the antiproliferative effect seen in treatment of BEZ235 alone (Fig. 5 ).
At present, the mechanism of this rescued cell viability upon autophagy inhibition is unknown. Apart from its apparent survival role, autophagy has also been suggested as having a cell destructive role by mediating autophagic cell death or type II physiological cell death, which is regulated by a molecular mechanism different from that of apoptosis (Li et al., 2013a) . Recently, cancer cells harboring activating mutations in RAS have been reported to have high basal levels of autophagy, which is required to maintain active tumor growth (Guo et al., 2011) . Furthermore, the expression of oncogenically mutated ras gene triggers cellular degeneration with biochemical and morphological features typical of autophagic cell death (Chi et al., 1999) . The excessive and persistent induction of autophagy has shown to lead to autophagic cell death under certain circumstances (Li et al., 2013b) . Thus, we tentatively suggest that high basal level of autophagy in HCT15 cells bearing RAS mutation and additional induction of autophagy in response to BEZ235 treatment result in autophagic cell death, and inhibition of autophagy with CQ treatment counteracts the the antiproliferative effect of BEZ235 on HCT15 CRC cells.
In summary, the present study using HCT15 CRC cells showed that BEZ235 effectively inhibits cell proliferation by G 1 arrest of cell cycle, which occurs via suppression of cyclin A expression. In addition, BEZ235 induces autophagy and inhibition of autophagy leads to the rescued cell viability, indicating that autophagy acts as cell destructive. Our findings provide novel insights into the role of autophagy as a cell death mechanism in the area of CRC therapeutics.
